On June 3, 2021, the Pennsylvania Department of Health released the following advisory:
- With the ongoing threat of COVID-19, providers are encouraged to consider all options for COVID-19 treatment.
- The FDA has issued Emergency Use Authorizations (EUAs) for anti-SARS-CoV-2 monoclonal antibodies, combination therapies bamlanivimab plus etesevimab and casirivimab plus imdevimab, and sotrovimab for use in non-hospitalized patients (age>12 and weighing>40kg), with laboratory confirmed SARS-CoV-2 infection and mild-to-moderate COVID-19 disease who are at high risk of progressing to severe disease and/or hospitalization.
- Bamlanivimab by itself no longer has an EUA as of 4/16/21, due to emerging data regarding SARS-CoV-2 viral variants’ resistance to this agent when used alone.
- It is recommended to administer these drugs as soon as possible after a positive SARS-CoV-2 test result, and within 10 days of symptom onset.
- Remdesivir continues to be the only FDA approved drug for the treatment of hospitalized patients with COVID-19 who require supplemental oxygen.
- Dexamethasone, and its equivalent corticosteroids, continues to be recommended for hospitalized patients who require mechanical ventilation; the greatest improvement of survival is shown in this group, and to a lesser degree in hospitalized patients who require supplemental oxygen. If corticosteroids are contraindicated, baricitinib plus remdesivir may be used.